Most-Upgraded Stocks Most-Downgraded Stocks NASDAQ:SGEN Seagen - SGEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $202.47 -0.61 (-0.30%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$201.77▼$204.4150-Day Range$133.49▼$203.0852-Week Range$105.43▼$204.41Volume1.36 million shsAverage Volume1.72 million shsMarket Capitalization$37.82 billionP/E RatioN/ADividend YieldN/APrice Target$188.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Seagen MarketRank™ ForecastAnalyst RatingHold2.35 Rating ScoreUpside/Downside7.0% Downside$188.33 Price TargetShort InterestHealthy0.97% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.64Based on 8 Articles This WeekInsider TradingSelling Shares$24.31 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.98) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector218th out of 996 stocksBiological Products, Except Diagnostic Industry41st out of 165 stocks 2.2 Analyst's Opinion Consensus RatingSeagen has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 6 buy ratings, 11 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $188.33, Seagen has a forecasted downside of 7.0% from its current price of $202.47.Amount of Analyst CoverageSeagen has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.97% of the outstanding shares of Seagen have been sold short.Short Interest Ratio / Days to CoverSeagen has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Seagen has recently decreased by 44.68%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSeagen does not currently pay a dividend.Dividend GrowthSeagen does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeagen has received a 45.57% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Brentuximab vedotin", "Tucatinib", and "Enfortumab vedotin" products. See details.Environmental SustainabilityThe Environmental Impact score for Seagen is -1.96. Previous Next 3.1 News and Social Media Coverage News SentimentSeagen has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Seagen this week, compared to 6 articles on an average week.Search InterestOnly 26 people have searched for SGEN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows15 people have added Seagen to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,314,068.00 in company stock.Percentage Held by Insiders27.30% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.25% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seagen are expected to grow in the coming year, from ($2.98) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seagen is -61.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seagen is -61.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeagen has a P/B Ratio of 13.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Seagen (NASDAQ:SGEN) StockSeagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.Read More Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address SGEN Stock News HeadlinesMarch 22, 2023 | marketbeat.com3 Dividend Contenders to Buy Now for Long-Term Gains Later (SGEN)Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains laterMarch 15, 2023 | marketbeat.comPfizer’s Latest Acquisition Strengthens the Case for PFE Stock (SGEN)Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stockApril 2, 2023 | Legacy Research (Affiliate) (Ad)Bear market expert makes new predictionNobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.April 2, 2023 | americanbankingnews.comSeagen (NASDAQ:SGEN) Coverage Initiated by Analysts at StockNews.comApril 1, 2023 | americanbankingnews.comSeagen Inc. (NASDAQ:SGEN) Receives Consensus Recommendation of "Hold" from BrokeragesMarch 25, 2023 | americanbankingnews.comSeagen (NASDAQ:SGEN) Now Covered by Analysts at StockNews.comMarch 24, 2023 | americanbankingnews.comSeagen (NASDAQ:SGEN) Stock Rating Lowered by Berenberg BankMarch 23, 2023 | americanbankingnews.comSeagen (NASDAQ:SGEN) PT Lowered to $129.00April 2, 2023 | Legacy Research (Affiliate) (Ad)Bear market expert makes new predictionNobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.March 22, 2023 | americanbankingnews.comTruist Financial Increases Seagen (NASDAQ:SGEN) Price Target to $229.00March 17, 2023 | finance.yahoo.comWhy Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?March 14, 2023 | finance.yahoo.comSeagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual MeetingMarch 14, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Seagen Inc. has obtained a Fair Price in its transaction with PfizerMarch 14, 2023 | msn.comSeagen Unusual Options Activity For March 13March 14, 2023 | markets.businessinsider.comBMO Capital downgrades Seagen (SGEN) to a HoldMarch 14, 2023 | barrons.comPfizer Rolls the Dice on Seagen in $43 Billion Deal. The Risks It Faces.March 14, 2023 | markets.businessinsider.comJMP Securities downgrades Seagen (SGEN) to a HoldMarch 13, 2023 | businesswire.comSEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGENMarch 13, 2023 | businesswire.comSGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to ShareholdersMarch 13, 2023 | finance.yahoo.comPfizer Invests $43 Billion to Battle CancerMarch 5, 2023 | finance.yahoo.comThe five-year returns have been impressive for Seagen (NASDAQ:SGEN) shareholders despite underlying losses increasingMarch 1, 2023 | finance.yahoo.comEstimating The Fair Value Of Seagen Inc. (NASDAQ:SGEN)February 25, 2023 | finance.yahoo.comA Seagen Inc. (NASDAQ:SGEN) insider lowered their holding by 16% earlier this yearFebruary 17, 2023 | finance.yahoo.comSeagen Full Year 2022 Earnings: Beats ExpectationsFebruary 16, 2023 | finance.yahoo.comWhy Seattle Genetics, Alkermes Are Currently Outperforming Their PeersFebruary 13, 2023 | finance.yahoo.comSeagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers SymposiumJanuary 19, 2023 | finance.yahoo.comSeagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal CancerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address SGEN Company Calendar Last Earnings2/15/2023Today4/02/2023Next Earnings (Estimated)4/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGEN CUSIP81257810 CIK1060736 Webwww.seattlegenetics.com Phone(425) 527-4000Fax425-527-4001Employees3,256Year Founded1998Price Target and Rating Average Stock Price Forecast$188.33 High Stock Price Forecast$229.00 Low Stock Price Forecast$129.00 Forecasted Upside/Downside-7.0%Consensus RatingHold Rating Score (0-4)2.35 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($3.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-610,310,000.00 Net Margins-31.10% Pretax Margin-30.69% Return on Equity-21.13% Return on Assets-16.79% Debt Debt-to-Equity RatioN/A Current Ratio3.42 Quick Ratio2.90 Sales & Book Value Annual Sales$1.96 billion Price / Sales19.27 Cash FlowN/A Price / Cash FlowN/A Book Value$15.10 per share Price / Book13.41Miscellaneous Outstanding Shares186,790,000Free Float135,796,000Market Cap$37.82 billion OptionableOptionable Beta0.53 Social Links Key ExecutivesDavid R. EpsteinChief Executive Officer & DirectorTodd E. SimpsonChief Financial OfficerVaughn B. HimesChief Technical OfficerRoger D. DanseyChief Medical OfficerGuy PadburySenior Vice President, Translational SciencesKey CompetitorsBiogenNASDAQ:BIIBGilead SciencesNASDAQ:GILDAmgenNASDAQ:AMGNBioNTechNASDAQ:BNTXargenxNASDAQ:ARGXView All CompetitorsInsiders & InstitutionsPalisade Capital Management LPSold 215 shares on 3/24/2023Ownership: 0.001%MetLife Investment Management LLCSold 217 shares on 3/23/2023Ownership: 0.004%Roger D DanseySold 10,000 sharesTotal: $2.00 M ($199.81/share)Daniel G WelchSold 544 sharesTotal: $108,800.00 ($200.00/share)Victory Capital Management Inc.Sold 4,045 shares on 3/10/2023Ownership: 0.071%View All Insider TransactionsView All Institutional Transactions SGEN Stock - Frequently Asked Questions Should I buy or sell Seagen stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares. View SGEN analyst ratings or view top-rated stocks. What is Seagen's stock price forecast for 2023? 17 equities research analysts have issued 12-month target prices for Seagen's stock. Their SGEN share price forecasts range from $129.00 to $229.00. On average, they expect the company's share price to reach $188.33 in the next year. This suggests that the stock has a possible downside of 7.0%. View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts. How have SGEN shares performed in 2023? Seagen's stock was trading at $128.51 on January 1st, 2023. Since then, SGEN stock has increased by 57.6% and is now trading at $202.47. View the best growth stocks for 2023 here. Are investors shorting Seagen? Seagen saw a decrease in short interest in March. As of March 15th, there was short interest totaling 1,820,000 shares, a decrease of 44.7% from the February 28th total of 3,290,000 shares. Based on an average daily volume of 1,310,000 shares, the short-interest ratio is presently 1.4 days. View Seagen's Short Interest. When is Seagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023. View our SGEN earnings forecast. How were Seagen's earnings last quarter? Seagen Inc. (NASDAQ:SGEN) issued its quarterly earnings data on Wednesday, February, 15th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.22. The biotechnology company had revenue of $528.20 million for the quarter, compared to analyst estimates of $479.81 million. Seagen had a negative trailing twelve-month return on equity of 21.13% and a negative net margin of 31.10%. The company's quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.95) earnings per share. What ETFs hold Seagen's stock? ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include Principal Healthcare Innovators ETF (BTEC), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), Goldman Sachs Future Health Care Equity ETF (GDOC) and Virtus LifeSci Biotech Products ETF (BBP). What guidance has Seagen issued on next quarter's earnings? Seagen updated its FY 2023 earnings guidance on Wednesday, February, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.14 billion-$2.24 billion, compared to the consensus revenue estimate of $2.30 billion. What is Clay B. Siegall's approval rating as Seagen's CEO? 107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Seagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA). What is Seagen's stock symbol? Seagen trades on the NASDAQ under the ticker symbol "SGEN." How do I buy shares of Seagen? Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Seagen's stock price today? One share of SGEN stock can currently be purchased for approximately $202.47. How much money does Seagen make? Seagen (NASDAQ:SGEN) has a market capitalization of $37.82 billion and generates $1.96 billion in revenue each year. The biotechnology company earns $-610,310,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. How many employees does Seagen have? The company employs 3,256 workers across the globe. Does Seagen have any subsidiaries? The following companies are subsidiares of Seagen: Cascadian Therapeutics.Read More How can I contact Seagen? Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001. This page (NASDAQ:SGEN) was last updated on 4/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.